ImmuCell Hires Chief Financial Officer
ImmuCell (Nasdaq: ICCC) has appointed Timothy C. Fiori as its new Chief Financial Officer. Fiori brings approximately 24 years of finance and commercial operating experience from IDEXX Laboratories in Westbrook, Maine. He holds a B.S. in Finance from the University of Maine (2001).
The company, which develops and manufactures products for dairy and beef cattle health, sees this hire as a strategic move in its growth plan. CEO Michael F. Brigham highlighted that Fiori will help leverage personnel, improve standard costing and financial reporting systems, and enhance business efficiencies.
ImmuCell's key products include First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.
ImmuCell (Nasdaq: ICCC) ha nominato Timothy C. Fiori come nuovo Chief Financial Officer. Fiori porta con sé circa 24 anni di esperienza nel settore finanziario e nelle operazioni commerciali, avendo lavorato presso IDEXX Laboratories a Westbrook, nel Maine. Ha conseguito una laurea in Finanza presso l'Università del Maine (2001).
L'azienda, che sviluppa e produce prodotti per la salute del bestiame da latte e da carne, considera questa assunzione come una mossa strategica nel suo piano di crescita. Il CEO Michael F. Brigham ha sottolineato che Fiori aiuterà a ottimizzare il personale, migliorare la contabilità standard e i sistemi di reporting finanziario, e aumentare l'efficienza aziendale.
I principali prodotti di ImmuCell includono First Defense®, che fornisce Immunità Immediata™ ai vitelli appena nati, e sta sviluppando Re-Tain®, un trattamento innovativo per la mastite subclinica nelle mucche da latte, senza le restrizioni di scarto del latte o di ritiro pre-macellazione richieste dalla FDA.
ImmuCell (Nasdaq: ICCC) ha nombrado a Timothy C. Fiori como su nuevo Director Financiero. Fiori aporta aproximadamente 24 años de experiencia en finanzas y operaciones comerciales de IDEXX Laboratories en Westbrook, Maine. Tiene una licenciatura en Finanzas de la Universidad de Maine (2001).
La empresa, que desarrolla y fabrica productos para la salud del ganado lechero y de carne, ve esta contratación como un movimiento estratégico en su plan de crecimiento. El CEO Michael F. Brigham destacó que Fiori ayudará a optimizar el personal, mejorar la contabilidad estándar y los sistemas de informes financieros, y aumentar la eficiencia empresarial.
Los productos clave de ImmuCell incluyen First Defense®, que proporciona Inmunidad Inmediata™ a los terneros recién nacidos, y está desarrollando Re-Tain®, un tratamiento novedoso para la mastitis subclínica en vacas lecheras sin las restricciones de descarte de leche o de retiro previo a la matanza requeridas por la FDA.
ImmuCell (Nasdaq: ICCC)는 Timothy C. Fiori를 새로운 최고 재무 책임자로 임명했습니다. Fiori는 메인주 웨스트브룩에 있는 IDEXX Laboratories에서 약 24년간의 금융 및 상업 운영 경험을 가지고 있습니다. 그는 메인 대학교에서 재무학 학사 학위를 취득했습니다 (2001).
우유 및 소고기 건강 제품을 개발하고 제조하는 이 회사는 이번 채용을 성장 계획의 전략적 조치로 보고 있습니다. CEO Michael F. Brigham은 Fiori가 인력을 활용하고, 표준 원가 및 재무 보고 시스템을 개선하며, 비즈니스 효율성을 높이는 데 도움을 줄 것이라고 강조했습니다.
ImmuCell의 주요 제품에는 신생 송아지에게 즉각적인 면역력을 제공하는 First Defense®와 FDA에서 요구하는 우유 폐기 또는 도살 전 철회 제한 없이 유선염의 아증상을 치료하기 위한 혁신적인 치료제인 Re-Tain®이 포함됩니다.
ImmuCell (Nasdaq: ICCC) a nommé Timothy C. Fiori comme nouveau directeur financier. Fiori apporte environ 24 ans d'expérience en finance et en exploitation commerciale d'IDEXX Laboratories à Westbrook, dans le Maine. Il est titulaire d'une licence en finance de l'Université du Maine (2001).
L'entreprise, qui développe et fabrique des produits pour la santé des bovins laitiers et de viande, considère cette embauche comme un mouvement stratégique dans son plan de croissance. Le PDG Michael F. Brigham a souligné que Fiori aidera à optimiser le personnel, améliorer la comptabilité standard et les systèmes de reporting financier, et accroître l'efficacité des affaires.
Les principaux produits d'ImmuCell incluent First Defense®, qui fournit une Immunité Immédiate™ aux veaux laitiers et de viande nouveau-nés, et développe Re-Tain®, un traitement novateur pour la mastite subclinique chez les vaches laitières sans les restrictions de rejet de lait ou de retrait avant l'abattage requises par la FDA.
ImmuCell (Nasdaq: ICCC) hat Timothy C. Fiori zum neuen Finanzvorstand ernannt. Fiori bringt etwa 24 Jahre Erfahrung in den Bereichen Finanzen und kommerzielle Betriebsführung von IDEXX Laboratories in Westbrook, Maine, mit. Er hat einen Bachelor-Abschluss in Finanzen von der Universität von Maine (2001).
Das Unternehmen, das Produkte für die Gesundheit von Milch- und Fleischrindern entwickelt und herstellt, sieht diese Einstellung als strategischen Schritt in seinem Wachstumsplan. CEO Michael F. Brigham betonte, dass Fiori helfen wird, das Personal zu optimieren, die Standardkosten und Finanzberichterstattungssysteme zu verbessern und die Effizienz des Unternehmens zu steigern.
Zu den Hauptprodukten von ImmuCell gehören First Defense®, das sofortige Immunität™ für neugeborene Milch- und Fleischkalb bietet, sowie die Entwicklung von Re-Tain®, einer neuartigen Behandlung für subklinische Mastitis bei Milchkühen, ohne die von der FDA geforderten Milchverwerfungs- oder Schlachtvorbereitungsbeschränkungen.
- Strategic hire of experienced CFO with 24 years at IDEXX Laboratories
- Expected improvements in financial systems and operational efficiency
- Development of Re-Tain® progressing to late stages
- None.
PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer.
Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activities.
“I am excited to join the ImmuCell leadership team at such a pivotal time in the Company’s development,” commented Mr. Fiori. “The product portfolio has tremendous proven value and great potential as we look to the future. I’m eager to start contributing immediately to the Company’s growth and development.”
“Adding Tim’s depth of experience and his great attitude to our team is a critical step in our ongoing growth plan,” added Michael F. Brigham, President and CEO. “He can help us leverage our personnel, improve our standard costing and financial reporting systems and find new efficiencies in all aspects of our business, to touch on just a few of the anticipated impacts that I believe Tim will have on our business.”
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; future improvements to internal financial and accounting systems; projections of future financial or operational performance; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. These statements are intended to provide management's current expectations of future events as of the date of this earnings release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements; forward-looking statements include other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
| Contacts: | Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com |
FAQ
What experience does Timothy Fiori bring to ImmuCell (ICCC) as the new CFO?
What are the main products in ImmuCell's (ICCC) current portfolio?
What are the expected improvements Timothy Fiori will bring to ImmuCell (ICCC)?
What advantages does ImmuCell's (ICCC) Re-Tain® treatment offer over traditional antibiotics?
